Vimseltinib (romvimza) approved for use in adults to treat tenosynovial giant cell tumours
The MHRA approved vimseltinib (Romvimza) to treat adult patients with tenosynovial giant cell tumour impacting movement or unsuitable for surgery via the I…
Impact analysis · 45/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The MHRA approved vimseltinib (Romvimza) to treat adult patients with tenosynovial giant cell tumour impacting movement or unsuitable for surgery via the International Recognition Procedure Route B on 14 August 2026.
Quantitative evidence
- Approval date: 14 August 2026
- Dosing schedule: twice weekly capsules
- Pivotal trial objective response rate not specified in press release
- No cost or pricing information provided
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Vimseltinib is a kinase inhibitor that slows TGCT growth by blocking the proteins driving tumour progression.
Market context
Deciphera Pharmaceuticals now holds UK marketing authorisation for a rare disease indication, enabling market entry.
Legal and regulatory context
Approval occurred via the International Recognition Procedure Route B, representing a streamlined regulatory pathway.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 80b541346379566d151984ae7aa8cfeefca8108f728298caab3f7eceaa9c4a00
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-14T13:09:13Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.